Kapa Biosystems and VWR International Sign Agreement
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Kapa Biosystems and VWR International, LLC announced that they have entered into a non-exclusive North American distribution agreement for Kapa Biosystems' line of next-generation PCR reagents.
Kapa Biosystems employs a high-throughput molecular evolution technology platform to engineer DNA-modifying enzymes for applications in DNA amplification, next-generation sequencing, and molecular diagnostics.
Under the terms of the agreement, VWR has the rights to distribute Kapa Biosystems' portfolio of products for applications such as high fidelity PCR, fast PCR, long range PCR, whole blood PCR, crude sample PCR, and single protocol PCR.
VWR, a global laboratory supply and distribution company with worldwide sales in excess of $3.7 billion in 2008, enables the advancement of the world’s most critical research through the distribution of a highly diversified product line to most of the top pharmaceutical and biotech companies, as well as industrial, educational and governmental organizations.
“Kapa Biosystems' high performance PCR reagents allow researchers to consolidate protocols, simplify workflows, save time, and achieve results not possible with reagents based on wild-type enzymes.”
"Kapa Biosystems' high performance PCR reagents allow researchers to consolidate protocols, simplify workflows, save time, and achieve results not possible with reagents based on wild-type enzymes," said Ron McEwan, CEO of Kapa Biosystems. "Kapa's agreement with VWR will significantly expand our ability to offer the benefits of these novel products to the broader life sciences research community."
The DNA polymerases contained in Kapa Biosystems' reagents have been engineered through a process of molecular evolution and possess amino acid modifications that confer improvements to the function of the enzymes.
Kapa Biosystems employs a high-throughput molecular evolution technology platform to engineer DNA-modifying enzymes for applications in DNA amplification, next-generation sequencing, and molecular diagnostics.
Under the terms of the agreement, VWR has the rights to distribute Kapa Biosystems' portfolio of products for applications such as high fidelity PCR, fast PCR, long range PCR, whole blood PCR, crude sample PCR, and single protocol PCR.
VWR, a global laboratory supply and distribution company with worldwide sales in excess of $3.7 billion in 2008, enables the advancement of the world’s most critical research through the distribution of a highly diversified product line to most of the top pharmaceutical and biotech companies, as well as industrial, educational and governmental organizations.
“Kapa Biosystems' high performance PCR reagents allow researchers to consolidate protocols, simplify workflows, save time, and achieve results not possible with reagents based on wild-type enzymes.”
"Kapa Biosystems' high performance PCR reagents allow researchers to consolidate protocols, simplify workflows, save time, and achieve results not possible with reagents based on wild-type enzymes," said Ron McEwan, CEO of Kapa Biosystems. "Kapa's agreement with VWR will significantly expand our ability to offer the benefits of these novel products to the broader life sciences research community."
The DNA polymerases contained in Kapa Biosystems' reagents have been engineered through a process of molecular evolution and possess amino acid modifications that confer improvements to the function of the enzymes.
